FMP-010 vaccine(Walter Reed Army Institute of Research)(FMP-010 vaccine(Walter Reed Army Institute of Research))

概要

基本信息

药物类型

治疗性疫苗、重组亚单位疫苗

别名

FMP 010 vaccine

靶点-

作用机制

免疫刺激剂

治疗领域

感染

在研适应症-

非在研适应症

疟疾恶性疟

原研机构

Walter Reed Army Institute of Research

在研机构-

非在研机构

GSK Plc

Walter Reed Army Institute of Research

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 FMP-010 vaccine(Walter Reed Army Institute of Research) 相关的临床试验

NCT00666380 / Completed临床1期IIT

Phase 1a Open-label Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B in Healthy Malaria-Naïve Adults

The purpose of this study is to determine whether an investigational malaria vaccine is safe and induces an immune response against malaria when tested in adults living in the United States.

开始日期2008-04-01

申办/合作机构

U S Army Medical Research & Development Command

[+3]

NCT02458092 / Completed临床1期IIT

Phase 1b Controlled Double Blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With Glaxo Smith Kline (GSK) Biologicals' Adjuvant AS01B

The purpose of this study is to determine whether an investigational malaria vaccine is safe and induces an immune response against malaria when tested in adults living in the United States.

开始日期2008-04-01

申办/合作机构

U S Army Medical Research & Development Command

[+3]

100 项与 FMP-010 vaccine(Walter Reed Army Institute of Research) 相关的临床结果

登录后查看更多信息

100 项与 FMP-010 vaccine(Walter Reed Army Institute of Research) 相关的转化医学

登录后查看更多信息

100 项与 FMP-010 vaccine(Walter Reed Army Institute of Research) 相关的专利（医药）

登录后查看更多信息

100 项与 FMP-010 vaccine(Walter Reed Army Institute of Research) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疟疾	临床1期	-	GSK Plc	2008-04-01
疟疾	临床1期	-	Walter Reed Army Institute of Research	2008-04-01
恶性疟	临床1期	肯尼亚	GSK Plc	2008-04-01
恶性疟	临床1期	美国	GSK Plc	2008-04-01
恶性疟	临床1期	美国	Walter Reed Army Institute of Research	2008-04-01
恶性疟	临床1期	肯尼亚	Walter Reed Army Institute of Research	2008-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02458092 (CTgov)	临床1期	疟疾	30	Rabipur (Rabies Vaccine Rabipur)	鏇選糧網網窪夢製顧淵(餘餘範蓋製鹹範廠夢壓) = 憲鹹觸淵積壓淵範鏇遞醖襯襯淵艱膚築糧鏇夢 (觸鹹糧願艱壓選積遞衊, 窪構鑰願糧襯衊鑰壓鬱 ~ 積選糧齋廠鏇餘繭醖簾) 更多	-	2020-06-09
				Plasmodium falciparum Malaria Protein 010 (FMP010) (50 µg of FMP010 Antigen in 0.5 mL AS01B Adjuvant)	遞淵醖積壓鬱鬱簾蓋願(醖襯獵願積壓鹽選齋鹹) = 艱觸醖壓壓廠網簾繭襯壓膚壓鑰襯艱鹽餘醖觸 (襯鑰蓋廠餘膚範廠廠鏇, 鹹構簾襯構網夢願膚糧 ~ 憲範網顧襯鑰製衊窪艱) 更多